LNK/SH2B3 loss of function promotes atherosclerosis and thrombosis

W Wang, Y Tang, Y Wang, L Tascau… - Circulation …, 2016 - Am Heart Assoc
W Wang, Y Tang, Y Wang, L Tascau, J Balcerek, W Tong, RL Levine, C Welch, AR Tall
Circulation research, 2016Am Heart Assoc
Rationale: Human genome-wide association studies have revealed novel genetic loci that
are associated with coronary heart disease. One such locus resides in LNK/SH2B3, which in
mice is expressed in hematopoietic cells and suppresses thrombopoietin signaling via its
receptor myeloproliferative leukemia virus oncogene. However, the mechanisms underlying
the association of LNK single-nucleotide polymorphisms with coronary heart disease are
poorly understood. Objective: To understand the functional effects of LNK single-nucleotide …
Rationale:
Human genome-wide association studies have revealed novel genetic loci that are associated with coronary heart disease. One such locus resides in LNK/SH2B3, which in mice is expressed in hematopoietic cells and suppresses thrombopoietin signaling via its receptor myeloproliferative leukemia virus oncogene. However, the mechanisms underlying the association of LNK single-nucleotide polymorphisms with coronary heart disease are poorly understood.
Objective:
To understand the functional effects of LNK single-nucleotide polymorphisms and explore the mechanisms whereby LNK loss of function impacts atherosclerosis and thrombosis.
Methods and Results:
Using human cord blood, we show that the common TT risk genotype (R262W) of LNK is associated with expansion of hematopoietic stem cells and enhanced megakaryopoiesis, demonstrating reduced LNK function and increased myeloproliferative leukemia virus oncogene signaling. In mice, hematopoietic Lnk deficiency leads to accelerated arterial thrombosis and atherosclerosis, but only in the setting of hypercholesterolemia. Hypercholesterolemia acts synergistically with LNK deficiency to increase interleukin 3/granulocyte-macrophage colony-stimulating factor receptor signaling in bone marrow myeloid progenitors, whereas in platelets cholesterol loading combines with Lnk deficiency to increase activation. Platelet LNK deficiency increases myeloproliferative leukemia virus oncogene signaling and AKT activation, whereas cholesterol loading decreases SHIP-1 phosphorylation, acting convergently to increase AKT and platelet activation. Together with increased myelopoiesis, platelet activation promotes prothrombotic and proatherogenic platelet/leukocyte aggregate formation.
Conclusions:
LNK (R262W) is a loss-of-function variant that promotes thrombopoietin/myeloproliferative leukemia virus oncogene signaling and platelet and leukocyte production. In mice, LNK deficiency is associated with both increased platelet production and activation. Hypercholesterolemia acts in platelets and hematopoietic progenitors to exacerbate thrombosis and atherosclerosis associated with LNK deficiency.
Am Heart Assoc